Skip to search formSkip to main contentSkip to account menu

dabrafenib

Known as: Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro- 
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (4)

Antineoplastic AgentsImidazolesOximesProtein Kinase Inhibitors
Breast Cancer Resistance Protein Inhibitors [MoA]NCIt Antineoplastic Agent TerminologyOrganic Anion Transporter 1 Inhibitors [MoA]dabrafenib 75 MG Oral Capsule [Tafinlar]

Narrower (3)

GSK 2118436Tafinlardabrafenib mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Melanoma: Time for adjuvant vemurafenib?
2018
2018
Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes
2017
2017
Dabrafenib Effective in Pediatric Glioma.
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E… 
2016
2016
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
TPS9596Background: The interaction between programmed death 1 (PD-1) and its ligands PD-L1 and PD-L2 represents a major pathway… 
Review
2015
Review
2015
Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
Treatment of advanced melanoma with selective BRAF and MEK inhibitors is associated with a series of mucocutaneous side effects… 
2014
2014
Therapeutics , Targets , and Chemical Biology The RAC 1 P 29 S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Following mutations in BRAF and NRAS, the RAC1 c.85C>T single-nucleotide variant (SNV) encoding P29S amino acid change represents… 
Review
2014
Review
2014
Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
O n January 9, 2014, the combination of trametinib and dabrafenib was granted accelerated approval by the US Food and Drug… 
2014
2014
[Targeted therapies for melanoma].
Since the discovery of activating mutations in the BRAF oncogene and also stimulation of immune mediated antitumor response in… 
2012
2012
Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365
2012
2012
New class of kinase inhibitors poised to join the anticancer arsenal
Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)